BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38170544)

  • 1. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    Harris E
    JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
    Carvalho T
    Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Mehta J
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
    [No Abstract]   [Full Text] [Related]  

  • 5. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Meisel R
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
    [No Abstract]   [Full Text] [Related]  

  • 6. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
    Frangoul H; Ho TW; Corbacioglu S
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107197
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives of Sickle Cell Disease Stakeholders on Heritable Genome Editing.
    Hollister BM; Gatter MC; Abdallah KE; Armsby AJ; Buscetta AJ; Byeon YJJ; Cooper KE; Desine S; Persaud A; Ormond KE; Bonham VL
    CRISPR J; 2019 Dec; 2(6):441-449. PubMed ID: 31742431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating Genetic Disorders Using State-Of-The-Art Technology.
    Jamal M; Ullah A; Ahsan M; Tyagi R; Habib Z; Khan FA; Rehman K
    Curr Issues Mol Biol; 2018; 26():33-46. PubMed ID: 28879854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 and Its Therapeutic Applications for Retinal Diseases.
    Lin WV; Stout JT; Weng CY
    Int Ophthalmol Clin; 2019; 59(1):3-13. PubMed ID: 30585915
    [No Abstract]   [Full Text] [Related]  

  • 10. Tweaking genes with CRISPR or viruses fixes blood disorders.
    Kaiser J
    Science; 2020 Dec; 370(6522):1254-1255. PubMed ID: 33303593
    [No Abstract]   [Full Text] [Related]  

  • 11. CRISPR gene therapy shows promise against blood diseases.
    Ledford H
    Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
    [No Abstract]   [Full Text] [Related]  

  • 12. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 13. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imagine CRISPR cures.
    Urnov FD
    Mol Ther; 2021 Nov; 29(11):3103-3106. PubMed ID: 34710352
    [No Abstract]   [Full Text] [Related]  

  • 16. Genome Editing for Sickle Cell Disease: A Little BCL11A Goes a Long Way.
    Hossain MA; Bungert J
    Mol Ther; 2017 Mar; 25(3):561-562. PubMed ID: 28190778
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation.
    Chu SH; Packer M; Rees H; Lam D; Yu Y; Marshall J; Cheng LI; Lam D; Olins J; Ran FA; Liquori A; Gantzer B; Decker J; Born D; Barrera L; Hartigan A; Gaudelli N; Ciaramella G; Slaymaker IM
    CRISPR J; 2021 Apr; 4(2):169-177. PubMed ID: 33876959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR in personalized medicine: Industry perspectives in gene editing.
    Hong A
    Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The realization of CRISPR gene therapy.
    Ma Y; Qi LS
    Nat Chem Biol; 2024 Jul; 20(7):791-795. PubMed ID: 38872012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.